#United States #Rockville #REGENXBIO #Diabetic Retinopathy #sura-vec

REGENXBIO Reports Groundbreaking Long-Term Efficacy Data for Surabgene Lomparvovec

At the recent American Society of Retina Specialists (ASRS) Annual Meeting in Montreal, REGENXBIO Inc. shared encouraging long-term results of their investigational gene therapy, surabgene lomparvovec, commonly known as sura-vec. This innovative treatment aims to address vision loss caused by conditions such as wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).

The Therapeutic Promise of Sura-vec

Sura-vec is a one-time gene therapy that targets chronic retinal diseases through advanced delivery methods. Data presented at the ASRS suggest that patients treated with sura-vec demonstrated stable or improved vision over five years. This outcome is particularly noteworthy given that many patients in the study had a history of requiring frequent anti-VEGF injections prior to receiving the treatment.

Stable Vision in Wet AMD: During this long-term follow-up, participants in the Phase I/IIa trials who received subretinal injections of sura-vec showed significant reduction in the need for ongoing anti-VEGF treatments, an often cumbersome protocol for managing wet AMD. Notably, no drug-related intraocular inflammation (IOI) was reported even in patients who did not receive prophylactic steroids.
Impact on Diabetic Retinopathy: In analyses of the Phase II ALTITUDE trial, sura-vec also positively impacted participants with non-proliferative diabetic retinopathy (NPDR). More than half of the participants reported a two-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at 2.5 years, demonstrating the therapy's potential to modify disease progression and prevent vision-threatening events.

Observations and Future Prospects

The results presented by REGENXBIO highlight the significance of a one-time treatment option that could mitigate the burdensome necessity for frequent injections and the associated risk of vision loss due to undertreatment. Furthermore, Steve Pakola, M.D., the Chief Medical Officer, emphasized that these data reinforce sura-vec’s potential to reshape treatment paradigms for chronic retinal diseases.

As REGENXBIO prepares to release topline data from pivotal studies, ATMOSPHERE and ASCENT, in Q4 2026, all eyes will be on how these results could influence clinical practice for treating retinal diseases. The pivotal trials are set to further compare sura-vec against standard anti-VEGF therapies, establishing a clearer framework for its long-term viability in clinical settings.

About REGENXBIO

Founded in 2009, REGENXBIO is at the forefront of gene therapy innovation, leveraging its proprietary AAV technology to develop one-time treatments aimed at rare and prevalent diseases. The company’s commitment to harnessing the curative potential of gene therapy aims to transform the lives of patients suffering from chronic conditions like wet AMD and DR.

As this powerful new therapy continues to evolve, it represents not just a scientific breakthrough, but a beacon of hope for millions of people facing potential vision loss.

For more updates on REGENXBIO and its groundbreaking technologies, you can visit their website or follow their latest announcements.